ADC Therapeutics (ADCT) EBITDA (2023 - 2026)

ADC Therapeutics has disclosed EBITDA across 4 years of filings, most recently posting -$25.2 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$25.2 million, up 11.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$128.8 million (up 7.84% YoY), and the FY2025 annual result was -$141.7 million, up 10.97% from the prior year.
• EBITDA came in at -$25.2 million for Q1 2026 at ADC Therapeutics, up from -$31.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$25.2 million in Q1 2026 to a low of -$59.5 million in Q1 2023.
• The 4-year median for EBITDA is -$35.9 million (2023), against an average of -$37.5 million.
• Peak annual rise in EBITDA reached 39.07% in 2025, while the deepest fall reached 52.02% in 2025.
• ADC Therapeutics' EBITDA stood at -$36.1 million in 2023, then gained by 1.62% to -$35.6 million in 2024, then grew by 12.92% to -$31.0 million in 2025, then grew by 18.48% to -$25.2 million in 2026.
• The last three EBITDA figures came in at -$25.2 million (Q1 2026), -$31.0 million (Q3 2025), and -$44.1 million (Q2 2025), per Business Quant data.